IDXX / IDEXX Laboratories, Inc. - Depositi SEC, Relazione annuale, dichiarazione di delega

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 000-19271 IDEXX LABO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2025 IDEXX LABORATORIES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2025 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction (Commission File Number) (IRS

IDEXX Laboratories Announces Second Quarter Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: John Ravis, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces Second Quarter Results · Achieves second quarter revenue growth of 11% as reported and 9% organic, supported by CAG Diagnostics recurring revenue growth of 9% as reported and 7% organic. · Advances IDEXX's innovation agenda and continues strong global commercial execution, result

IDEXX Laboratories Elects Joseph L. (Jay) Hooley to Board of Directors

EXHIBIT 99.1 IDEXX Laboratories Elects Joseph L. (Jay) Hooley to Board of Directors WESTBROOK, Maine, July 10, 2025 – IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the election of Joseph L. (Jay) Hooley to the Company's Board of Directors, effective July 10, 2025. "We are excited to welcome Jay to the IDEXX Board of Directors," said Lawrence

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 10, 2025 IDEXX LABORATORIES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 10, 2025 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction (Commission File Number) (IRS

Conflict Minerals Report for the calendar year ended December 31, 2024.

Exhibit 1.01 Conflict Minerals Report - 2024 Overview IDEXX Laboratories, Inc. has included this Conflict Minerals Report as an exhibit to its Form SD for the calendar year ended December 31, 2024 as provided for in Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Form SD (collectively, the “Conflict Minerals Rule”). The date of filing of this Conflict Min

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM SD SPECIALIZED DISCLOSURE REPORT _________________________ IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) One IDEXX Drive, Westbrook, Maine 4092 (Address of princip

Amended and Restated By-Laws of IDEXX Laboratories, Inc., amended through May 7, 2025

EXHIBIT 3.2 AMENDED AND RESTATED BY-LAWS OF IDEXX LABORATORIES, INC. (Amended through May 7, 2025) BY-LAWS TABLE OF CONTENTS ARTICLE 1 − STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 2 1.5 Notice by Electronic Transmission 2 1.6 Voting List 2 1.7 Quorum 2 1.8 Adjournments 3 1.9 Voting and Proxies 3 1.1 Action at Meeting 3 1.11 Nomination

Amended and Restated Certificate of Incorporation of IDEXX Laboratories, Inc., dated May 7, 2025

EXHIBIT 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF IDEXX LABORATORIES, INC. (originally AgriTech Systems, Inc.) (Incorporated December 19, 1983) IDEXX Laboratories, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby integrate into this instrument all of the provisions of its certifica

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2025 IDEXX LABORATORIES INC /DE IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) IDEXX LABORATORIES INC /DE Delaware 000-19271 01-0393723 (State

IDEXX Laboratories Announces First Quarter Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: John Ravis, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces First Quarter Results · Achieves first quarter revenue growth of 4% as reported and 5% organic, supported by CAG Diagnostics recurring revenue growth of 3% as reported and 4.5% organic. · Organic revenue growth supported by benefits from IDEXX execution drivers, including continu

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 1, 2025 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction (Commission File Number) (IRS Em

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 000-19271 IDEXX LAB

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) þ Filed by the Registrant ¨ Filed by a Party other than the Registr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) þ Filed by the Registrant ¨ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) þ Filed by the Registrant ¨ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) þ Filed by the Registrant ¨ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: þ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin

Amendment No. 9 to U.S. Supply Agreement effective as of October 31, 2024, among IDEXX Operations, Inc., the Company and Ortho

EXHIBIT 10.10 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY ASTERISKS [**], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. AMENDMENT NO. 9 THIS AMENDMENT NO. 9 (“Amendment”), effective as of October 31, 2024 (the “Amendment Effective Date”), is between IDEXX Operations, Inc., a Delaware corporati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER: 0-19271 IDEXX LABORATORIES,

Form of Change in Control Agreement, by and between each of the Company’s Executive Officers, other than the Chief Executive Officer

Exhibit 10.56 FORM OF CHANGE IN CONTROL AGREEMENT THIS CHANGE IN CONTROL AGREEMENT is made as of [ ], 20[ ] (this “Agreement”), by and between IDEXX Laboratories, Inc., a Delaware corporation (the “Company”), and (the “Executive”) [and amends and restates in its entirety the [Amended and Restated] Executive Employment Agreement by and between the Company and the Executive dated as of [ ]]. The Com

Summary of Executive Incentive Plan

Exhibit 10.30 IDEXX LABORATORIES, INC. Executive Incentive Plan Summary of Bonus Determination Process As of Performance Year beginning 1/1/2025 Overview Annual performance-based cash bonuses are paid to the individuals of the Executive Team, pursuant to our Executive Incentive Plan (the 'Executive Incentive Plan'), which program is adopted by the Compensation and Talent Committee historically in

Amendment No. 7 to European Supply Agreement effective as of October 31, 2024, among IDEXX B.V., the Company and Ortho

EXHIBIT 10.18 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY ASTERISKS [**], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. AMENDMENT NO. 7 THIS AMENDMENT NO. 7 (“Amendment”), effective as of October 31, 2024 (the “Amendment Effective Date”), is between IDEXX B.V., a organized under the laws of th

Subsidiaries of the Company

Exhibit 21 IDEXX LABORATORIES, INC. SUBSIDIARIES OF THE REGISTRANT Legal Entity Name Jurisdiction of Incorporation or Formation 342 Saco Street, LLC Maine Beijing IDEXX Laboratories Co. Limited China IDEXX Animana B.V. Netherlands IDEXX Brasil Laboratórios Ltda. Brazil IDEXX Brasil Participações Ltda. Brazil IDEXX Diagnostic Limited Ireland IDEXX Diavet AG Schwyz IDEXX Distribution, Inc. Massachus

Nonqualified Deferred Compensation Plan

EXHIBIT 10.53 IDEXX Deferred Compensation Plan Effective Date December 6, 2024 IDEXX Deferred Compensation Plan Article I Establishment and Purpose 1 Article II Definitions 1 Article III Eligibility and Participation 6 Article IV Deferrals 6 Article V Company Contributions 11 Article VI Payments from Accounts 12 Article VII Valuation of Account Balances; Investments 15 Article VIII Administration

Insider Trading Policy

EXHIBIT 19.1 Updated as of January 1, 2025 INSIDER TRADING POLICY From time to time, employees1 and members of the Board of Directors of IDEXX Laboratories, Inc. (“Board Members”) may possess or have access to material information concerning the business or prospects of IDEXX Laboratories, Inc. and its subsidiaries (collectively, “IDEXX” or the “Company”) that, for valid business reasons, has not

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 13, 2025 IDEXX LABORATORIES INC /DE IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) IDEXX LABORATORIES INC /DE Delaware 000-19271 01-0393723 (

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 3, 2025 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction (Commission File Number) (I

IDEXX Laboratories Announces Fourth Quarter and Full Year 2024 Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: John Ravis, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces Fourth Quarter and Full Year 2024 Results ▪ Achieves fourth quarter revenue growth of 6% as reported and on an organic basis, driven by CAG Diagnostics recurring revenue growth of 6% reported and 7% organic ▪ Solid growth supported by continued benefits from IDEXX execution drive

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 6, 2024 IDEXX LABORATORIES INC /DE IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) IDEXX LABORATORIES INC /DE Delaware 000-19271 01-0393723 (S

IDEXX Laboratories Announces Increase in Share Repurchase Program Authorization

Exhibit 99.1 IDEXX Laboratories Announces Increase in Share Repurchase Program Authorization WESTBROOK, Maine, December 9, 2024—IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that the Company’s Board of Directors authorized an increase in its ongoing share repurchase program, authorizing the repurchase of up to five million additional shares

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 3, 2024 IDEXX LABORATORIES INC /DE IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) IDEXX LABORATORIES INC /DE Delaware 000-19271 01-0393723 (S

IDEXX Announces CFO Transition Brian McKeon to Retire from IDEXX in June 2025 Andrew Emerson, Senior Vice President, Corporate and CAG Finance, to Serve as IDEXX’s Next CFO

Exhibit 99.1 IDEXX Announces CFO Transition Brian McKeon to Retire from IDEXX in June 2025 Andrew Emerson, Senior Vice President, Corporate and CAG Finance, to Serve as IDEXX’s Next CFO WESTBROOK, Maine, November 21, 2024 — IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Brian McKeon has decided to retire from IDEXX effective June 1, 2025

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 20, 2024 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction (Commission File Number) (

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2024 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction (Commission File Number) (I

Via Diligent Messenger

Exhibit 99.1 Via Diligent Messenger November 8, 2024 To:         Jay Mazelsky, President, IDEXX Laboratories CC:        Sharon Underberg, Secretary to the Board of Directors RE: Resignation from the IDEXX Board of Directors Dear Jay, I am writing to resign from the Board of Directors of IDEXX, Laboratories, Inc. (the “Company”), and its Finance Committee, effective today, November 8, 2024. My deci

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 31, 2024 IDEXX LABORATORIES INC /DE IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) IDEXX LABORATORIES INC /DE Delaware 000-19271 01-0393723 (S

IDEXX Laboratories Announces Third Quarter Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: John Ravis, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces Third Quarter Results ▪ Achieves third quarter revenue growth of 7% as reported and 6% organic, supported by CAG Diagnostics recurring revenue growth of 7% as reported and organic. ▪ Organic revenue growth supported by benefits from IDEXX execution drivers including continued sol

Third Amended and Restated Employment Agreement, dated August 2, 2024, by and between the Company and Jonathan J. Mazelsky

Exhibit 10.1 THIRD AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT THIS THIRD AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made as of August 2, 2024 (the “Effective Date”) by and between IDEXX Laboratories, Inc., a Delaware corporation (the “Company”), and Jonathan (Jay) Mazelsky (the “Executive”) and amends and restates in its entirety the Second Amended and Restated Employ

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 31, 2024 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction (Commission File Number) (I

IDEXX Laboratories Announces Third Quarter Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: John Ravis, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces Third Quarter Results ▪ Achieves third quarter revenue growth of 7% as reported and 6% organic, supported by CAG Diagnostics recurring revenue growth of 7% as reported and organic. ▪ Organic revenue growth supported by benefits from IDEXX execution drivers including continued sol

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 31, 2024 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 000-19271 IDE

Form of Change in Control Agreement, by and between each of the Company’s Executive Officers, other than the Chief Executive Officer

Exhibit 10.2 FORM OF CHANGE IN CONTROL AGREEMENT THIS CHANGE IN CONTROL AGREEMENT is made as of [ ], 20[ ] (this “Agreement”), by and between IDEXX Laboratories, Inc., a Delaware corporation (the “Company”), and (the “Executive”) [and amends and restates in its entirety the [Amended and Restated] Executive Employment Agreement by and between the Company and the Executive dated as of [ ]]. The Comp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 6, 2024 IDEXX LABORATORIES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 6, 2024 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction (Commission File Number) (IRS

Third Amended and Restated Employment Agreement, dated August 2, 2024, by and between the Company and Jonathan J. Mazelsky

Exhibit 10.3 FORM OF CHANGE IN CONTROL AGREEMENT THIS CHANGE IN CONTROL AGREEMENT is made as of [ ], 20[ ] (this “Agreement”), by and between IDEXX Laboratories, Inc., a Delaware corporation (the “Company”), and (the “Executive”) [and amends and restates in its entirety the [Amended and Restated] Executive Employment Agreement by and between the Company and the Executive dated as of [ ]]. The Comp

IDEXX Laboratories Announces Second Quarter Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: John Ravis, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces Second Quarter Results · Achieves second quarter revenue growth of 6% as reported and 7% organic, supported by CAG Diagnostics recurring revenue growth of 6% as reported and 7% organic. · Solid growth supported by continued benefits from IDEXX execution drivers, including record

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 000-19271 IDEXX LA

Form of Change in Control Agreement, by and between each of the Company’s Executive Officers, other than the Chief Executive Officer

Exhibit 10.4 THIRD AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT THIS THIRD AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made as of August 2, 2024 (the “Effective Date”) by and between IDEXX Laboratories, Inc., a Delaware corporation (the “Company”), and Jonathan (Jay) Mazelsky (the “Executive”) and amends and restates in its entirety the Second Amended and Restated Employ

Suspension of Rights Agreement dated May 2, 2024 to the Fourth Amended and Restated Credit Agreement, by and among the Borrowers, JPMorgan Chase Bank, N.A., as Administrative Agent, JPMorgan Chase Bank, N.A., Toronto Branch, as Toronto Agent and the Lenders from time to time party thereto

Exhibit 10.2 SUSPENSION OF RIGHTS AGREEMENT To: JPMorgan Chase Bank, N.A., as Administrative Agent, and JPMorgan Chase Bank, N.A., Toronto Branch, as Toronto Agent From: IDEXX LABORATORIES, INC., a Delaware corporation (the “Administrative Borrower”), IDEXX DISTRIBUTION, INC., a Massachusetts corporation (“IDEXX DISTRIBUTION”), IDEXX OPERATIONS, INC., a Delaware corporation (“IDEXX OPERATIONS”), O

Form of Employee Stock Option Agreement for grants in 2013 to 2015

Exhibit 10.5 Employee Stock Option Agreement Granted Under IDEXX Laboratories, Inc. 2009 Stock Incentive Plan 1. Grant of Option. IDEXX Laboratories, Inc., a Delaware corporation (the “Company”), hereby grants to the employee named in this Agreement (the “Optionee”), an option, pursuant to the Company’s 2009 Stock Incentive Plan (the “Plan”), to purchase, in whole or in part, the number of shares

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM SD SPECIALIZED DISCLOSURE REPORT _________________________ IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 (State or other jurisdiction of incorporation) (Commission file number) One IDEXX Drive, Westbrook, Maine 4092 (Address of principal executive offices) (ZIP code) Sharon E. Underberg Executiv

Conflict Minerals Report for the calendar year ended December 31, 202

Exhibit 1.01 Conflict Minerals Report - 2023 Overview IDEXX Laboratories, Inc. has included this Conflict Minerals Report as an exhibit to its Form SD for the calendar year ended December 31, 2023 as provided for in Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Form SD (collectively, the “Conflict Minerals Rule”). The date of filing of this Conflict Min

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 6, 2024 IDEXX LABORATORIES INC /DE IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) IDEXX LABORATORIES INC /DE Delaware 000-19271 01-0393723 (State

Consulting Agreement effective May 7, 2024 by and between IDEXX Laboratories, Inc. and James F. Polewaczyk

CERTAIN IDENTIFIED INFORMATION MARKED WITH ASTERISKS [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT BOTH (i) IS NOT MATERIAL AND (ii) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL EXHIBIT 10.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 1, 2024 IDEXX LABORATORIES, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 1, 2024 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction (Commission File Number) (IRS Em

IDEXX Laboratories Announces First Quarter Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: John Ravis, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces First Quarter Results ▪ Achieves first quarter revenue growth of 7% as reported and organic, supported by CAG Diagnostics recurring revenue growth of 7% as reported and organic ▪ Solid growth supported by continued benefits from IDEXX execution drivers including double-digit year

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 000-19271 IDEXX L

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) þ Filed by the Registrant ¨ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) þ Filed by the Registrant ¨ Filed by a Party other than the Registr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) þ Filed by the Registrant ¨ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin

IDEXX Laboratories, Inc. Clawback Policy

Exhibit 97.1 IDEXX LABORATORIES, INC. AMENDED & RESTATED CLAWBACK POLICY Adopted by the Board: October 18, 2023 1.Purpose. The Board believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has, therefore, adopte

Summary of Executive Incentive Plan

Exhibit 10.28 IDEXX LABORATORIES, INC. Executive Incentive Plan Summary of Bonus Determination Process As of Performance Year beginning 1/1/2024 Overview Annual performance-based cash bonuses are paid to the individuals of the Executive Team, pursuant to our Executive Incentive Plan (the 'Executive Incentive Plan'), which program is adopted by the Compensation and Talent Committee historically in

Employee Leveraged Restricted Stock Unit Agreement

Exhibit 10.50 Employee Leveraged Restricted Stock Unit Agreement Granted under IDEXX Laboratories, Inc. 2018 Stock Incentive Plan 1.Grant of Restricted Stock Units. a.Grant. IDEXX Laboratories, Inc., a Delaware corporation (the “Company”), hereby grants to the Participant a Restricted Stock Unit Award consisting of the number of Restricted Stock Units (“RSUs”) stated in this Restricted Stock Unit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 0-19271 IDEXX LABORATORIE

Subsidiaries of the Company

Exhibit 21 IDEXX LABORATORIES, INC. SUBSIDIARIES OF THE REGISTRANT Legal Entity Name Jurisdiction of Incorporation or Formation 342 Saco Street, LLC Maine Beijing IDEXX Laboratories Co. Limited China ezyVet US, Inc. Delaware IDEXX Animana B.V. Netherlands IDEXX Brasil Laboratórios Ltda. Brazil IDEXX Brasil Participações Ltda. Brazil IDEXX Diagnostic Limited Ireland IDEXX Diavet AG Schwyz IDEXX Dis

IDXX / IDEXX Laboratories, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01165-idexxlaboratoriesinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: IDEXX Laboratories Inc Title of Class of Securities: Common Stock CUSIP Number: 45168D104 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to

IDEXX Announces Fourth Quarter and Full Year Results

Exhibit 99.1 IDEXX Announces Fourth Quarter and Full Year Results Achieves fourth quarter revenue growth of 9% reported and 8% organic, driven by CAG Diagnostics recurring revenue growth of 11% reported and 10% organic Solid growth supported by continued benefits from IDEXX execution drivers, including 11% year-over-year expansion of IDEXX's global premium instrument installed base Delivers fourth

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 5, 2024 IDEXX Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction of incorporation) (Commissi

IDXX / Idexx Laboratories, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: IDEXX Laboratories Inc Title of Class of Securities: Common Stock CUSIP Number: 45168D104 Date of Event Which Requires Filing of this Statement: November 30, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is file

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 5, 2023 IDEXX LABORATORI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 5, 2023 IDEXX LABORATORIES INC /DE IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) IDEXX LABORATORIES INC /DE Delaware 000-19271 01-0393723 (S

IDEXX Laboratories Announces Third Quarter Results

Exhibit 99.1 IDEXX Laboratories Announces Third Quarter Results Achieves third quarter revenue growth of 9% reported and 8% organic, driven by CAG Diagnostics recurring revenue growth of 10% reported and 9% organic Solid revenue growth reflects benefits from IDEXX execution drivers including double-digit year-over-year installed base growth across global premium instrument platforms Delivers EPS o

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 1, 2023 IDEXX Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction of incorporation) (Commissi

Letter agreement between Ortho-Clinical Diagnostics, Inc., IDEXX B.V. and IDEXX Operations, Inc. dated July 28, 2023.

Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY ASTERISKS [**], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. July 28, 2023 IDEXX Laboratories, Inc. One IDEXX Drive Westbrook, ME 04092 Subject: Agreements Extensions Reference is made to (i) the agreement dated October 16, 2003 (such a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 000-19271 IDE

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 1, 2023 IDEXX Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 000-19271 IDEXX LA

IDEXX Laboratories Announces Second Quarter Results

Exhibit 99.1 IDEXX Laboratories Announces Second Quarter Results Records second quarter revenue growth of 10% reported and 10% organic, driven by CAG Diagnostics recurring revenue growth of 11% reported and 12% organic Achieves record second quarter global premium instrument placements, supporting 11% annual installed base growth Delivers EPS of $2.67, representing 71% growth as reported and 77% o

IDEXX Laboratories Elects Irene Chang Britt to Board of Directors

Exhibit 99.1 IDEXX Laboratories Elects Irene Chang Britt to Board of Directors WESTBROOK, Maine, July 12, 2023 - IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the election of Irene Chang Britt, a former executive at Campbell Soup Company, to the Company's Board of Directors, effective July 11, 2023. "We are pleased to welcome Irene to the ID

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 11, 2023 IDEXX LABORATORIES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 11, 2023 IDEXX LABORATORIES INC /DE IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) IDEXX LABORATORIES INC /DE Delaware 000-19271 01-0393723 (Stat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM SD SPECIALIZED DISCLOSURE REPORT _________________________ IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 (State or other jurisdiction of incorporation) (Commission file number) One IDEXX Drive, Westbrook, Maine 4092 (Address of principal executive offices) (ZIP code) Sharon E. Underberg Executiv

Conflict Minerals Report for the calendar year ended December 31, 2022.

U.S. Securities and Exchange Commission You’ve Exceeded the SEC’s Traffic Limit Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 17, 2023 IDEXX LABORATORIES I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 17, 2023 IDEXX LABORATORIES INC /DE IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) IDEXX LABORATORIES INC /DE Delaware 000-19271 01-0393723 (State

UNITED STATES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 2, 2023 IDEXX Laboratories, Inc. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 000-19271 IDEXX L

IDEXX Laboratories Announces First Quarter Results

EX-99.1 2 a53391037ex991.htm EXHIBIT 99.1 Exhibit 99.1 IDEXX Laboratories Announces First Quarter Results Achieves first quarter revenue growth of 8% reported and 10% organic, driven by CAG Diagnostics recurring revenue growth of 9% reported and 12% organic Strong organic revenue growth supported by IDEXX execution drivers, including record first quarter global premium instrument placements Delive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) þ Filed by the Registrant ¨ Filed by a Party other than the Registr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) þ Filed by the Registrant ¨ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) þ Filed by the Registrant ¨ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 0-19271 IDEXX LABORATORIE

Summary of Executive Incentive Plan

Exhibit 10.27 IDEXX LABORATORIES, INC. Executive Incentive Plan Summary of Bonus Determination Process As of Performance Year beginning 1/1/2023 Overview Annual performance-based cash bonuses are paid to the individuals of the Executive Team, pursuant to our Executive Incentive Plan (the “Executive Incentive Plan”), which program is adopted by the Compensation Committee historically in February of

Subsidiaries of the Company (filed herewith).

Exhibit 21 IDEXX LABORATORIES, INC. SUBSIDIARIES OF THE REGISTRANT Legal Entity Name Jurisdiction of Incorporation or Formation 342 Saco Street, LLC Maine Beijing IDEXX Laboratories Co. Limited China ezyVet US, Inc. Delaware IDEXX Animana B.V. Netherlands IDEXX Brasil Laboratórios Ltda. Brazil IDEXX Brasil Participações Ltda. Brazil IDEXX Diagnostic Limited Ireland IDEXX Diavet AG Schwyz IDEXX Dis

IDXX / IDEXX Laboratories, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: IDEXX Laboratories Inc. Title of Class of Securities: Common Stock CUSIP Number: 45168D104 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is fil

IDEXX Laboratories Announces Fourth Quarter and Full Year 2022 Results

Exhibit 99.1 IDEXX Laboratories Announces Fourth Quarter and Full Year 2022 Results Achieves fourth quarter revenue growth of 3% reported and 7% organic, driven by CAG Diagnostics recurring revenue growth of 4% reported and 8% organic Solid growth supported by continued benefits from IDEXX execution drivers, including 13% year-over-year expansion of IDEXX's global premium instrument installed base

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 06, 2023 IDEXX LABORATORIES INC /DE (Exact name of Registrant as Specified in Its Charter) Delaware 000-19271 01-0393723 (State or Other Jurisdiction of Incorporation) (Commi

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 1, 2022 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 000-19271 IDE

IDEXX Laboratories Announces Third Quarter Results

Exhibit 99.1 IDEXX Laboratories Announces Third Quarter Results Achieves third quarter revenue growth of 4% reported and 8% organic, driven by CAG Diagnostics recurring revenue growth of 5% reported and 9% organic, building on high prior year growth Continued strong demand for diagnostic services and excellent commercial execution support record third quarter premium instrument placements, driving

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 20, 2022 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction of incorporation) (Commissi

Amendment No. 1, dated as of October 20, 2022, to the Fourth Amended and Restated Credit Agreement, among the Company, IDEXX Distribution, Inc., IDEXX Operations, Inc., OPTI Medical Systems, Inc., IDEXX Laboratories Canada Corporation, IDEXX B.V., IDEXX Laboratories B.V., and IDEXX Laboratories GmbH, as borrowers, the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, JPMorgan Chase Bank, N.A., Toronto Branch, as Toronto agent, and the other parties thereto

Exhibit 10.1 EXECUTION VERSION AMENDMENT NO. 1 Dated as of October 20, 2022 to FOURTH AMENDED AND RESTATED CREDIT AGREEMENT Dated as of December 9, 2021 THIS AMENDMENT NO. 1 (this ?Amendment?) is made as of October 20, 2022 by and among IDEXX Laboratories, Inc., a Delaware corporation (the ?Administrative Borrower?), IDEXX Distribution, Inc., a Massachusetts corporation, IDEXX Operations, Inc., a

IDEXX Laboratories Announces Second Quarter Results

Exhibit 99.1 IDEXX Laboratories Announces Second Quarter Results Achieves second quarter revenue growth of 4% reported and 6.5% organic, driven by CAG Diagnostics recurring revenue growth of 4% reported and 7% organic, building on high prior year growth Solid demand for diagnostic services and strong IDEXX execution support record second quarter premium instrument placements, driving 15% growth in

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2022 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 000-19271 IDEXX LA

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 13, 2022 IDEXX LABORATORIES INC /DE IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) IDEXX LABORATORIES INC /DE Delaware 000-19271 01-0393723 (Stat

Amended and Restated By-Laws of IDEXX Laboratories, Inc., amended through July 13, 2022

EXHIBIT 3.2 AMENDED AND RESTATED BY-LAWS OF IDEXX LABORATORIES, INC. (Amended through July 13, 2022) BY-LAWS TABLE OF CONTENTS Article 1 ? STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 1 1.6 Quorum 2 1.7 Adjournments 2 1.8 Voting and Proxies 2 1.9 Action at Meeting 3 1.10 Nomination of Directors. 3 1.11 Action without Me

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2022 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM SD SPECIALIZED DISCLOSURE REPORT _________________________ IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 (State or other jurisdiction of incorporation) (Commission file number) One IDEXX Drive, Westbrook, Maine 4092 (Address of principal executive offices) (ZIP code) Sharon E. Underberg Executiv

Conflict Mineral Report for the calendar year ended December 31, 2021.

Exhibit 1.01 Conflict Minerals Report - 2021 Overview IDEXX Laboratories, Inc. has included this Conflict Minerals Report as an exhibit to its Form SD for the calendar year ended December 31, 2021 as provided for in Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), and Form SD (collectively, the ?Conflict Minerals Rule?). The date of filing of this Conflict Min

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2022 IDEXX LABORATORIES INC /DE IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) IDEXX LABORATORIES INC /DE Delaware 000-19271 01-0393723 (State

Form of Confidential Information, Work Product, and Restrictive Covenant Agreement with each of the Company’s Executive Officers.

Exhibit 10.1 CONFIDENTIAL INFORMATION, WORK PRODUCT, AND RESTRICTIVE COVENANT AGREEMENT This Confidential Information, Work Product, and Restrictive Covenant Agreement (?Agreement?) is made by and between IDEXX Laboratories, Inc. and its parents, subsidiaries, affiliates, predecessors, successors and assigns (the ?Company?) and the undersigned individual (?Employee?) (collectively, the ?Parties? a

IDEXX Laboratories Announces First Quarter Results

Exhibit 99.1 IDEXX Laboratories Announces First Quarter Results Achieves first quarter revenue growth of 8% reported and organic, driven by CAG Diagnostics recurring revenue growth of 8% reported and 9% organic, building on high prior year growth Continued strong sector demand supports record first quarter premium instrument placements, driving CAG Diagnostics capital instrument revenue growth of

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 4, 2022 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 000-19271 IDEXX L

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant o Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin

European Supply Agreement, effective as of October 17, 2003, among IDEXX Europe B.V., the Company and Ortho

Exhibit 10.10 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY ASTERISKS, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. AGREEMENT THIS AGREEMENT is made effective as of the 17th day of October, 2003, between IDEXX Europe B.V., a corporation organized under the law of The Netherlands whose principal

Form of Director Restricted Stock Unit

Exhibit 10.29 Director Restricted Stock Unit Agreement Granted Under IDEXX Laboratories, Inc. 2018 Stock Incentive Plan 1.Grant of Restricted Stock. IDEXX Laboratories, Inc., a Delaware corporation (the ?Company?), hereby grants to the Participant a Restricted Stock Unit Award consisting of the number of Restricted Stock Units (?RSUs?) stated in this Agreement, including any exhibit, appendix or a

Amendment No. 4 to U.S. Supply Agreement effective as of December 28, 2011, among IDEXX Operations, Inc., the Company and Ortho

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY ASTERISKS, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.

U.S. Supply Agreement, effective as of October 16, 2003, among IDEXX Operations, Inc., the Company and Ortho-Clinical Diagnostics, Inc. (“Ortho”)

Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY ASTERISKS, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. AGREEMENT THIS AGREEMENT is made effective as of the 16th day of October, 2003, between IDEXX Operations, Inc., a Delaware corporation whose principal place of business is at 6100

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 0-19271 IDEXX LABORATORIE

Letter Agreement between Ortho-Clinical Diagnostics, Inc. and IDEXX Operations, Inc. dated November 2, 2021

Exhibit 10.19 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY ASTERISKS, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. November 2, 2021 IDEXX Laboratories, Inc. One IDEXX Drive Westbrook, ME 04091 ATTN: John Hart Corporate VP Worldwide Operations IDEXX Laboratories, Inc. Subject: Catalyst Capacity

Form of Director Stock Option Agreement

Exhibit 10.28 Director Stock Option Agreement Granted Under IDEXX Laboratories, Inc. 2018 Stock Incentive Plan 1. Grant of Option. IDEXX Laboratories, Inc., a Delaware corporation (the ?Company?), hereby grants to the member of the Board named on the opposite side of this Agreement (the ?Optionee?), an option, pursuant to the Company?s 2018 Stock Incentive Plan (the ?Plan?), to purchase, in whole

Amendment No. 8 to U.S. Supply Agreement effective as of September 1, 2021, among IDEXX Operations, Inc., the Company and Ortho

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY ASTERISKS, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.

Amendment No. 6 to European Supply Agreement effective as of September 1, 2021, among IDEXX Europe B.V., the Company and Ortho.

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY ASTERISKS, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.

Amendment No. 5 to U.S. Supply Agreement effective as of December 9, 2013, among IDEXX Operations, Inc., the Company and Ortho

EXECUTION COPY CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY ASTERISKS, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.

Amendment No. 4 to European Supply Agreement effective as of December 9, 2013, among IDEXX Europe B.V., the Company and Ortho

EXECUTION COPY CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY ASTERISKS, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.

Restated Director Deferred Compensation Plan, as amended

Exhibit 10.22 IDEXX Laboratories, Inc. DIRECTOR DEFERRED COMPENSATION PLAN Restated Effective as of October 13, 2021 The Director Deferred Compensation Plan of IDEXX Laboratories, Inc. (the ?Plan?) was initially established effective July 1, 2003 to provide an additional mechanism for satisfying stock ownership guidelines, as well as to provide a vehicle for non-employee Directors to defer the rec

Form of Employee Restricted Stock Unit for grants beginning in 2022

Exhibit 10.41 Employee Restricted Stock Unit Agreement Granted Under IDEXX Laboratories, Inc. 2018 Stock Incentive Plan 1.Grant of Restricted Stock Units. (a)Grant. IDEXX Laboratories, Inc., a Delaware corporation (the ?Company?), hereby grants to the Participant a Restricted Stock Unit Award consisting of the number of Restricted Stock Units (?RSUs?) stated in this Restricted Stock Unit Agreement

Form of Stock Option Agreement for grants made to Jonathan J. Mazelsky in 2022

Exhibit 10.44 CEO Stock Option Agreement Granted Under IDEXX Laboratories, Inc. 2018 Stock Incentive Plan 1. Grant of Option. (a)Grant. IDEXX Laboratories, Inc., a Delaware corporation (the ?Company?), pursuant to the Company?s 2018 Stock Incentive Plan (the ?Plan?) and this Employee Stock Option Agreement, including any exhibit, appendix or addendum hereto (the ?Agreement?), hereby grants to the

Amendment No. 1 to European Supply Agreement effective as of January 1, 2005, among IDEXX Europe B.V., the Company and Ortho

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY ASTERISKS, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.

Subsidiaries of the Company (filed herewith).

Exhibit 21 IDEXX LABORATORIES, INC. SUBSIDIARIES OF THE REGISTRANT Legal Entity Name Jurisdiction of Incorporation or Formation 342 Saco Street, LLC Maine Beijing IDEXX Laboratories Co. Limited China ezyVet US, Inc. Delaware IDEXX Animana B.V. Netherlands IDEXX Brasil Laborat?rios Ltda. Brazil IDEXX Brasil Participa??es Ltda. Brazil IDEXX Diagnostic Limited Ireland IDEXX Diavet AG Schwyz IDEXX Dis

Form of Restricted Stock Unit for grants made to Jonathan J. Mazelsky in 2022

Exhibit 10.43 CEO Restricted Stock Unit Agreement Granted Under IDEXX Laboratories, Inc. 2018 Stock Incentive Plan 1.Grant of Restricted Stock Units. (a)Grant. IDEXX Laboratories, Inc., a Delaware corporation (the ?Company?), hereby grants to the Participant a Restricted Stock Unit Award consisting of the number of Restricted Stock Units (?RSUs?) stated in this Restricted Stock Unit Agreement, inc

Form of Employee Stock Option Agreement for grants beginning in 2022.

Exhibit 10.34 Employee Stock Option Agreement Granted Under IDEXX Laboratories, Inc. 2018 Stock Incentive Plan 1. Grant of Option. (a)Grant. IDEXX Laboratories, Inc., a Delaware corporation (the ?Company?), pursuant to the Company?s 2018 Stock Incentive Plan (the ?Plan?) and this Employee Stock Option Agreement, including any exhibit, appendix or addendum hereto (the ?Agreement?), hereby grants to

Amendment No. 1 to U.S. Supply Agreement effective as of January 1, 2005, among IDEXX Operations, Inc., the Company and Ortho

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY ASTERISKS, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.

Form of Employee High-Performer Restricted Stock Unit beginning in 2022

Exhibit 10.42 Restricted Stock Unit Agreement Granted Under IDEXX Laboratories, Inc. 2018 Stock Incentive Plan 1.Grant of Restricted Stock. (a)Grant. IDEXX Laboratories, Inc., a Delaware corporation (the ?Company?), hereby grants to the Participant a Restricted Stock Unit Award consisting of the number of Restricted Stock Units (?RSUs?) stated in this Agreement, including any exhibit, appendix or

Amendment No. 3 to European Supply Agreement effective as of December 28, 2011, among IDEXX Europe B.V., the Company and Ortho

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY ASTERISKS, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.

IDXX / IDEXX Laboratories, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: IDEXX Laboratories Inc. Title of Class of Securities: Common Stock CUSIP Number: 45168D104 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is file

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 2, 2022 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction of incorporation) (Commissi

IDEXX Laboratories Announces Fourth Quarter and Full Year 2021 Results

Exhibit 99.1 IDEXX Laboratories Announces Fourth Quarter and Full Year 2021 Results WESTBROOK, Maine, Feb. 2, 2022 /PRNewswire/ - Achieves 11% fourth quarter revenue growth as reported and 10.5% organic, driven by 13% CAG Diagnostics recurring revenue growth (reported and organic) Strong growth supported by record instrument placements, resulting in 14% year-over-year expansion of IDEXX's global p

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 9, 2021 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction of incorporation) (Commissi

Fourth Amended and Restated Credit Agreement, dated as of December 9, 2021, among the Company, IDEXX Distribution, Inc., IDEXX Operations, Inc., OPTI Medical Systems, Inc., IDEXX Laboratories Canada Corporation, IDEXX B.V., IDEXX Laboratories B.V., and IDEXX Laboratories GmbH, as borrowers, the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, JPMorgan Chase Bank, N.A., Toronto Branch, as Toronto agent, and the other parties thereto.

EX-10.1 2 d264618dex101.htm EX-10.1 Exhibit 10.1 EXECUTION VERSION FOURTH AMENDED AND RESTATED CREDIT AGREEMENT dated as of December 9, 2021 among IDEXX LABORATORIES, INC., IDEXX DISTRIBUTION, INC., IDEXX OPERATIONS, INC., OPTI MEDICAL SYSTEMS, INC., IDEXX LABORATORIES CANADA CORPORATION, IDEXX B.V., IDEXX LABORATORIES B.V., and IDEXX LABORATORIES GMBH, as Borrowers, The Lenders Party Hereto, JPMO

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 2, 2021 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction of incorporation) (Commissi

Amendment No. 5 to European Supply Agreement effective as of July 9, 2019, among IDEXX Europe B.V., the Company and Ortho (filed herewith).

Exhibit 10.2 AMENDMENT NO.5 TO AGREEMENT THIS AMENDMENT NO.5 TO AGREEMENT (this ?Amendment?) is made effective as of July 9, 2019, between IDEXX Europe B.V., a corporation organized under the law of The Netherlands (?IDEXX?) and Ortho-Clinical Diagnostics, Inc., a New York corporation with offices at 100 Indigo Creek Drive, Rochester, New York, U.S.A. (?OCD?). WHEREAS, OCD and IDEXX have entered i

Amendment No. 7 to U.S. Supply Agreement effective as of July 9, 2019, among IDEXX Operations, Inc., the Company and Ortho-Clinical Diagnostics, Inc. (“Ortho”) (filed herewith).

Exhibit 10.1 AMENDMENT NO. 7 TO AGREEMENT THIS AMENDMENT NO.7 TO AGREEMENT (this ?Amendment?) is made effective as of July 9, 2019, between IDEXX Operations, Inc., a Delaware corporation whose principal place of business is at 6100 east Shelby Drive, Memphis Tennessee 38141, U.S.A. (?IDEXX?) and Ortho-Clinical Diagnostics, Inc., a New York corporation with offices at 100 Indigo Creek Drive, Roches

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 000-19271 IDE

IDEXX Laboratories Announces Third Quarter Results

Exhibit 99.1 IDEXX Laboratories Announces Third Quarter Results WESTBROOK, Maine, Nov. 2, 2021 /PRNewswire/ - Achieves third quarter revenue growth of 12% as reported and 10% on an organic basis compared to high prior year growth levels Results driven by continued strong CAG business momentum, reflected in CAG Diagnostics recurring revenue growth of 13% reported and 11.5% organic and record Q3 glo

IDEXX Laboratories Announces Second Quarter Results

Exhibit 99.1 IDEXX Laboratories Announces Second Quarter Results WESTBROOK, Maine, July 30, 2021 /PRNewswire/ - Achieves reported revenue growth of 30% and organic revenue growth of 25%, driven by CAG Diagnostics recurring revenue growth of 30% as reported and 26% organic Delivers EPS of $2.34, representing 36% growth as reported and 33% on a comparable basis Increases 2021 revenue guidance to $3,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 000-19271 IDEXX LA

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2021 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM SD SPECIALIZED DISCLOSURE REPORT _________________________ IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) One IDEXX Drive, Westbrook, Maine 4092 (Address of principal executive off

for the calendar year ended December 31, 2020.

Exhibit 1.01 Conflict Minerals Report - 2020 Overview IDEXX Laboratories, Inc. has included this Conflict Minerals Report as an exhibit to its Form SD for the calendar year ended December 31, 2020 as provided for in Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Form SD (collectively, the "Conflict Minerals Rule"). The date of filing of this Conflict Min

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2021 IDEXX LABORATORIES INC /DE IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) IDEXX LABORATORIES INC /DE Delaware 000-19271 01-0393723 (State

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 4, 2021 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction of incorporation) (Commission Fi

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 000-19271 IDEXX L

IDEXX Laboratories Announces First Quarter Results

EX-99.1 2 d154540dex991.htm EX-99.1 Exhibit 99.1 IDEXX Laboratories Announces First Quarter Results WESTBROOK, Maine, May 4, 2021 /PRNewswire/ - Achieves reported revenue growth of 24% and organic growth of 21%, driven by CAG Diagnostics recurring revenue growth of 27% as reported and 23% organic Delivers EPS of $2.35, representing 82% growth as reported and 73% on a comparable basis Increases 202

Form of CEO Stock Option Agreement for grant in 2021

Exhibit 10.1 Employee Stock Option Agreements Granted Under IDEXX Laboratories, Inc. 2018 Stock Incentive Plan 1. Grant of Option. (a)Grant. IDEXX Laboratories, Inc., a Delaware corporation (the ?Company?), pursuant to the Company?s 2018 Stock Incentive Plan (the ?Plan?) and this Employee Stock Option Agreement, including any exhibit, appendix or addendum hereto (the ?Agreement?), hereby grants to

Form of CEO Restricted Stock Agreement for grant in 2021

Exhibit 10.2 Employee Restricted Stock Unit Agreement Granted Under IDEXX Laboratories, Inc. 2018 Stock Incentive Plan 1.Grant of Restricted Stock Units. (a)Grant. IDEXX Laboratories, Inc., a Delaware corporation (the ?Company?), hereby grants to the Participant a Restricted Stock Unit Award consisting of the number of Restricted Stock Units (?RSUs?) stated in this Restricted Stock Unit Agreement,

- DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant o Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 0-19271 IDEXX LABORATORIE

Summary of Executive Incentive Plan (filed as Exhibit No. 10.22 to Annual Report on Form 10-K for the year December 31, 2020, File No. 0-19271, and incorporated herein by reference).

Exhibit 10.22 IDEXX LABORATORIES, INC. Executive Incentive Plan Summary of Bonus Determination Process As of Performance Year beginning 1/1/2021 Overview Annual performance-based cash bonuses are paid to the individuals of the Executive Team, pursuant to our Executive Incentive Plan (the ?Executive Incentive Plan?), which program is adopted by the Compensation Committee historically in February of

IDEXX Laboratories, Inc. 1997 Employee Stock Purchase Plan, as amended (filed herewith).

Exhibit 10.19 IDEXX LABORATORIES, INC. 1997 EMPLOYEE STOCK PURCHASE PLAN As of December 2, 2020 The purpose of this Plan is to provide eligible employees of IDEXX Laboratories, Inc. (the ?Company?) and certain of its subsidiaries with opportunities to purchase shares of the Company?s common stock, $.10 par value (the ?Common Stock?), commencing on July 1, 1997. The Plan was initially adopted by th

of the Company (filed herewith).

Exhibit 21 IDEXX LABORATORIES, INC. SUBSIDIARIES OF THE COMPANY Legal Entity Name Jurisdiction of Incorporation or Formation 342 Saco Street, LLC Maine Beijing IDEXX-Yuanheng Laboratories Co. Limited China IDEXX Animana B.V. Netherlands IDEXX Brasil Laborat?rios Ltda. Brazil IDEXX Brasil Participa??es Ltda. Brazil IDEXX Diagnostic Limited Ireland IDEXX Diavet AG Schwyz IDEXX Distribution, Inc. Mas

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)*

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: IDEXX Laboratories Inc. Title of Class of Securities: Common Stock CUSIP Number: 45168D104 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is file

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 09, 2021 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction of incorporation) (Commiss

IDEXX Laboratories Announces Fourth Quarter and Full Year 2020 Results

Exhibit 99.1 IDEXX Laboratories Announces Fourth Quarter and Full Year 2020 Results WESTBROOK, Maine, Feb. 2, 2021 /PRNewswire/ - Achieves fourth quarter reported revenue growth of 19% and organic growth of 17%, driven by CAG Diagnostics recurring revenue reported growth of 23% and organic growth of 21% High revenue growth supported by sustained strong global trends in pet healthcare Delivers full

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 02, 2021 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction of incorporation) (Commiss

IDEXX Laboratories Elects Dr. Asha S. Collins to Board of Directors

Exhibit 99.1 IDEXX Laboratories Elects Dr. Asha S. Collins to Board of Directors WESTBROOK, Maine, Nov. 12, 2020 /PRNewswire/ - IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, announced today the election of Dr. Asha S. Collins, Head of U.S. Clinical Operations of Genentech, a biotechnology company and

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 11, 2020 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction of incorporation) (Commiss

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 29 2020 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction of incorporation) (Commissio

Letter Agreement between Ortho-Clinical Diagnostics, Inc. and IDEXX

Exhibit 10.1 Certain identified information marked with [**] has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed 1001 US Route 202 Raritan, NJ 08869-0606 July 10, 2020 IDEXX Operations, Inc. One IDEXX Drive Westbrook, ME 04092 and IDEXX Europe B.V. Koolhovenlaan 20 119 NE-Schipol-Rijk The Netherlands RE: Pricing 2019

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 000-19271 IDE

IDEXX Laboratories Announces Third Quarter Results

Exhibit 99.1 IDEXX Laboratories Announces Third Quarter Results WESTBROOK, Maine, Oct. 29, 2020 /PRNewswire/ - Achieves revenue growth of 19% on a reported basis and 18% on an organic basis driven by Companion Animal Group Diagnostics recurring revenue growth of 23% reported and 21% organic High revenue growth supported by sustained strong global recovery in the pet healthcare market Delivers EPS

IDEXX Laboratories Announces Second Quarter Results

Exhibit 99.1 IDEXX Laboratories Announces Second Quarter Results WESTBROOK, Maine, July 31, 2020 /PRNewswire/ - Reports revenue growth of 3% on a reported basis and 4% on an organic basis driven by Companion Animal Group Diagnostics recurring revenue growth of 7% reported and organic Revenue results supported by global "V-shaped" recovery in the pet healthcare market Delivers EPS of $1.72, represe

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 31 2020 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction of incorporation) (Commission F

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 000-19271 IDEXX LA

Conflict Minerals Report for the calendar year ended December 31, 2019

Exhibit 1.01 Conflict Minerals Report - 2019 Overview IDEXX Laboratories, Inc. has included this Conflict Minerals Report as an exhibit to its Form SD for the calendar year ended December 31, 2019 as provided for in Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Form SD (collectively, the "Conflict Minerals Rule"). The date of filing of this Conflict Min

- SD

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) One IDEXX Drive, Westbrook, Maine 04092 (Address of principal executive of

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 6 2020 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction of incorporation) (Commission Fil

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 30, 2020 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction of incorporation) (Commission

Waiver to U.S. Supply Agreement, effective as of October 16, 2003, as amended, among IDEXX Operations, Inc., the Company and Ortho-Clinical Diagnostics, Inc. dated as of April 7, 2020

Exhibit 10.1 April 7th, 2020 From: IDEXX Laboratories, Inc. One IDEXX Drive Westbrook, ME 04092 To: Ortho-Clinical Diagnostics, Inc. Attn: Jonathan Smith – Senior Director, Alliance Management 1001 US Highway 202 Raritan, New Jersey 08869 RE: Temporary waiver of distribution Territory restrictions To Jonathan Smith, Reference is made to the agreement entered into between IDEXX Operations, Inc. (“I

Amendment to Senior Advisory Agreement, dated April 14, 2020, by and between the Company and Mr. Jonathan W. Ayers (filed as Exhibit 10.2 to Quarterly Report on Form 10-Q filed April 30, 2020, File No. 0-19271, and incorporated herein by reference).

EX-10.2 3 a102ayerssenioradvisor.htm EXHIBIT 10.2 Exhibit 10.2 April 14, 2020 Jonathan W. Ayers Re: Amendment to Senior Advisory Agreement Dear Jon: This letter (this “Amendment”) confirms the mutual agreement between you and IDEXX Laboratories, Inc. (the “Company,” and together with its subsidiaries and affiliates, “IDEXX”) to amend the Senior Advisory Agreement, dated October 23, 2019 (the “Seni

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 000-19271 IDEXX L

IDEXX Laboratories Announces First Quarter Results

Exhibit 99.1 IDEXX Laboratories Announces First Quarter Results WESTBROOK, Maine, April 30, 2020 /PRNewswire/ - Reports revenue growth of 9% on a reported and organic basis driven by Companion Animal Group ("CAG") Diagnostics recurring revenue growth of 10% reported and organic Delivers EPS of $1.29, representing 10% growth on a reported basis and 13% on a comparable constant currency basis Enhanc

Amendment to Note Purchase Agreement, dated as of April 10, 2020, among the Company, as issuer, New York Life Insurance Company, New York Life Insurance and Annuity Corporation and New York Life Insurance and Annuity Corporation Institutionally Owned Life Insurance Separate Account (BOLI 30C), as purchasers

Exhibit 10.5 Execution Version AMENDMENT TO NOTE PURCHASE AGREEMENT This Amendment to Note Purchase Agreement, dated as of April 10, 2020 (this “Amendment Agreement”) is made by and among IDEXX Laboratories, Inc., a Delaware corporation (the “Company”), each of the Subsidiary Guarantors set forth on the signature pages to this Amendment Agreement (together with the Company, collectively, the “Cred

Amendment to Note Purchase Agreement, dated as of April 10, 2020, among the Company, as issuer, New York Life Insurance Company, New York Life Insurance and Annuity Corporation and New York Life Insurance and Annuity Corporation Institutionally Owned Life Insurance Separate Account (BOLI 30C), as purchasers

Exhibit 10.4 Execution Version AMENDMENT TO NOTE PURCHASE AGREEMENT This Amendment to Note Purchase Agreement, dated as of April 10, 2020 (this “Amendment Agreement”) is made by and among IDEXX Laboratories, Inc., a Delaware corporation (the “Company”), each of the Subsidiary Guarantors set forth on the signature pages to this Amendment Agreement (together with the Company, collectively, the “Cred

Second Amendment to Amended and Restated Multi-Currency Note Purchase and Private Shelf Agreement, dated as of April 10, 2020, among the Company, as issuer, each of the Subsidiary Guarantors (as defined therein), Prudential and each of the holders of the Notes (as defined therein)

Exhibit 10.3 Execution Version SECOND AMENDMENT TO AMENDED AND RESTATED MULTI-CURRENCY NOTE PURCHASE AND PRIVATE SHELF AGREEMENT This Second Amendment to Amended and Restated Multi-Currency Note Purchase and Private Shelf Agreement, dated as of April 10, 2020 (this “Amendment Agreement”) is made by and among IDEXX Laboratories, Inc., a Delaware corporation (the “Company”), each of the Subsidiary G

Amendment to Amended and Restated Multi-Currency Note Purchase and Private Shelf Agreement, dated as of May 9, 2019, among the Company, as issuer, each of the Subsidiary Guarantors (as defined therein), Prudential and each of the holders of the Notes (as defined therein)

Exhibit10.2 EXECUTION COPY AMENDMENT TO NOTE PURCHASE AND PRIVATE SHELF AGREEMENT This Amendment to Note Purchase and Private Shelf Agreement, dated as of May 9, 2019 (this“Amendment Agreement”) is made by and among IDEXX Laboratories, Inc., a Delaware corporation (the “Company”), PGIM, Inc. (formerly known as Prudential Investment Management, Inc., “Prudential”), and each of the holders of the No

Third Amended and Restated Credit Agreement, dated as of April 14, 2020, among the Company, IDEXX Distribution, Inc., IDEXX Operations, Inc., OPTI Medical Systems, Inc., IDEXX Laboratories Canada Corporation, IDEXX Europe B.V., and IDEXX Holding B.V., as borrowers, the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, JPMorgan Chase Bank, N.A., Toronto Branch, as Toronto agent, and the other parties thereto

Exhibit 10.6 Execution Version THIRD AMENDED AND RESTATED CREDIT AGREEMENT dated as of April 14, 2020 among IDEXX LABORATORIES, INC., IDEXX DISTRIBUTION, INC., IDEXX OPERATIONS, INC., OPTI MEDICAL SYSTEMS, INC., IDEXX LABORATORIES CANADA CORPORATION, IDEXX EUROPE B.V., and IDEXX HOLDING B.V., as Borrowers, The Lenders Party Hereto, JPMORGAN CHASE BANK, N.A. as Administrative Agent, JPMORGAN CHASE

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 10, 2020 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction of incorporation) (Commission

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 2, 2020 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction of incorporation) (Commission

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2020 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction of incorporation) (Commission

Second Amendment to Multicurrency Note Purchase and Private Shelf Agreement, dated March 23, 2020, among the Company, as issuer, each of the Subsidiary Guarantors (as defined therein), Metropolitan Life Insurance Company and each of the holders of the Notes (as defined therein)

Exhibit 10.1 Execution Version Second Amendment To Multicurrency Note Purchase and Private Shelf Agreement This Second Amendment to Multicurrency Note Purchase and Private Shelf Agreement, dated as of March 23, 2020 (this “Second Amendment”), is made by and among IDEXX Laboratories, Inc., a Delaware corporation (the “Company”), each of the Subsidiary Guarantors set forth on the signature pages to

IDXX / IDEXX Laboratories, Inc. DEF 14A - - DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) þ Filed by the Registrant ¨ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Defin

IDXX / IDEXX Laboratories, Inc. DEFA14A - - DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) þ Filed by the Registrant o Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin

Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

EXHIBIT 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of IDEXX Laboratories Inc.’s common stock is a summary. This summary is subject to the General Corporation Law of the State of Delaware (the “DGCL”) and the complete text of IDEXX Laboratories, Inc.’s restated certificate of incorporation, as ame

Summary of Executive Incentive Plan (filed herewith).

Exhibit 10.22 IDEXX LABORATORIES, INC. Executive Incentive Plan Summary of Bonus Determination Process As of Performance Year beginning 1/1/2020 Overview Annual performance-based cash bonuses are paid to the individuals of the Executive Team, pursuant to our Executive Incentive Plan (the “Executive Incentive Plan”), which program is adopted by the Compensation Committee historically in February of

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 0-19271 IDEXX LABORATORIES

Subsidiaries of the Company (filed herewith).

Exhibit 21 IDEXX LABORATORIES, INC. SUBSIDIARIES OF THE COMPANY Legal Entity Name Jurisdiction of Incorporation or Formation 342 Saco Street, LLC Maine Beijing IDEXX-Yuanheng Laboratories Co. Limited China IDEXX Animana B.V. Netherlands IDEXX Brasil Laboratórios Ltda. Brazil IDEXX Brasil Participações Ltda. Brazil IDEXX Diagnostic Limited Ireland IDEXX Diavet AG Schwyz IDEXX Distribution, Inc. Mas

Form of Employee Stock Option Agreement for grants in 2020 and 2021

EXHIBIT 10.28 Employee Stock Option Agreement Granted Under IDEXX Laboratories, Inc. 2018 Stock Incentive Plan 1. Grant of Option. (a)Grant. IDEXX Laboratories, Inc., a Delaware corporation (the “Company”), pursuant to the Company’s 2018 Stock Incentive Plan (the “Plan”) and this Employee Stock Option Agreement, including any exhibit, appendix or addendum hereto (the “Agreement”), hereby grants to

Form of Employee Restricted Stock Unit for grants in 2020 and 2021

EXHIBIT 10.32 Employee Restricted Stock Unit Agreement Granted Under IDEXX Laboratories, Inc. 2018 Stock Incentive Plan 1. Grant of Restricted Stock Units. (a)Grant. IDEXX Laboratories, Inc., a Delaware corporation (the “Company”), hereby grants to the Participant a Restricted Stock Unit Award consisting of the number of Restricted Stock Units (“RSUs”) stated in this Restricted Stock Unit Agreemen

Form of Director Restricted Stock Unit (filed as Exhibit 10.24 to 2019 Form 10-K, and incorporated herein by reference).

EXHIBIT 10.24 Restricted Stock Unit Agreement Granted Under IDEXX Laboratories, Inc. 2018 Stock Incentive Plan 1. Grant of Restricted Stock. IDEXX Laboratories, Inc., a Delaware corporation (the “Company”), hereby grants to the Participant a Restricted Stock Unit Award consisting of the number of Restricted Stock Units (“RSUs”) stated in this Agreement. Each RSU represents the right to receive one

IDXX / IDEXX Laboratories, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: IDEXX Laboratories Inc Title of Class of Securities: Common Stock CUSIP Number: 45168D104 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed

IDEXX Laboratories Announces Fourth Quarter and Full Year 2019 Results

EX-99.1 Exhibit 99.1 IDEXX Laboratories Announces Fourth Quarter and Full Year 2019 Results WESTBROOK, Maine, Jan. 31, 2020 /PRNewswire/ — • Achieves revenue growth in Q4 of 10% on a reported and organic basis, driven by CAG Diagnostics recurring revenue reported and organic growth of 11% • Reports 19% year-over-year increase in Catalyst placements at new and competitive accounts in Q4, supporting

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 31, 2020 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction of incorporation) (Commissi

IDEXX Laboratories Announces Third Quarter Results

Exhibit 99.1 IDEXX Laboratories Announces Third Quarter Results WESTBROOK, Maine, Oct. 31, 2019 /PRNewswire/ - Reports revenue growth of 11% on a reported basis and 12% on an organic basis, driven by Companion Animal Group ("CAG") Diagnostics recurring revenue growth of 13% reported and 14% organic Delivers EPS of $1.24, representing 18% growth on a reported basis and 21% on a comparable constant

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2019 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in charter) Delaware 000-19271 01-0393723 (State or Other Jurisdiction (Commission File Number) (I.R.S

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 000-19271 IDE

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2019 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in charter) Delaware 000-19271 01-0393723 (State or Other Jurisdiction (Commission File Number) (I.R.S

Senior Advisory Agreement, dated October 23, 2019, by and between the Company. and Mr. Jonathan W. Ayers (filed as Exhibit 10.2 to Current Report on Form 8-K filed October 24, 2019, File No. 0-19271, and incorporated herein by reference).

Exhibit 10.2 Execution Copy October 23, 2019 Jonathan W. Ayers Re: Senior Advisory Agreement Dear Jon: This letter agreement (this “Senior Advisory Agreement”), confirms the mutual agreement between you and IDEXX Laboratories, Inc. (the “Company,” and together with its subsidiaries and affiliates, “IDEXX”) for you to serve as senior advisor to the Company (“Senior Advisor”) and provide certain adv

Second Amended and Restated Employment Agreement, dated October 23, 2019, by and between the Company and Jonathan (Jay) Mazelsky (filed as Exhibit 10.3 to Current Report on Form 8-K filed October 24, 2019, File No. 0-19271, and incorporated herein by reference).

Exhibit 10.3 Execution Copy SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT THIS SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made as of October 23, 2019 (the “Effective Date”) by and between IDEXX Laboratories, Inc., a Delaware corporation (the “Company”), and Jonathan (Jay) Mazelsky (the “Executive”) and amends and restates in its entirety the Amended and Res

IDEXX Laboratories Announces Leadership Changes Jay Mazelsky Appointed President and Chief Executive Officer and Elected to IDEXX Board Jonathan Ayers Will Continue as a Member of the IDEXX Board and Serve as a Senior Advisor to the Company Lawrence

Exhibit 99.1 IDEXX Laboratories Announces Leadership Changes Jay Mazelsky Appointed President and Chief Executive Officer and Elected to IDEXX Board Jonathan Ayers Will Continue as a Member of the IDEXX Board and Serve as a Senior Advisor to the Company Lawrence Kingsley Assumes Role of Independent Chairman of the Board WESTBROOK, Maine, October 24, 2019—IDEXX Laboratories, Inc. (NASDAQ: IDXX), a

Mutual Separation Agreement, dated October 23, 2019, by and between the Company and Mr. Jonathan W. Ayers (filed as Exhibit 10.1 to Current Report on Form 8-K filed October 24, 2019, File No. 0-19271, and incorporated herein by reference).

Exhibit 10.1 Execution Copy October 23, 2019 Jonathan W. Ayers Re: Mutual Separation Agreement Dear Jon: This letter agreement (this “Mutual Separation Agreement”) and a separate senior advisor agreement being entered into by you and IDEXX Laboratories, Inc. (the “Company”) simultaneously herewith (the “Senior Advisory Agreement”) set forth the terms under which your tenure as an employee of the C

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 5, 2019 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction (Commission File Number) (IRS

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 1, 2019 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction (Commission File Number) (IRS

IDEXX Laboratories Announces Second Quarter Results

Exhibit 99.1 IDEXX Laboratories Announces Second Quarter Results WESTBROOK, Maine, Aug. 1, 2019 /PRNewswire/ - Reports revenue growth of 7% on a reported basis and 9% on an organic basis, driven by Companion Animal Group ("CAG") Diagnostics recurring revenue growth of 9% reported and 11% organic Delivers EPS of $1.43, representing 16% growth on a reported basis and 19% on a comparable constant cur

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 000-19271 IDEXX LA

IDXX / IDEXX Laboratories, Inc. CORRESP - -

July 31, 2019 Mr. Mark Brunhofer Division of Corporation Finance Office of Healthcare & Insurance United States Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: IDEXX Laboratories, Inc. Form 10-K for the Fiscal Year Ended December 31, 2018 Filed on February 15, 2019 File No. 000-19271 Dear Mr. Brunhofer: This letter sets forth below the detailed response of IDEXX Labora

July 24, 2019

Exhibit 99.1 July 24, 2019 Statement from Jon Ayers: As you know, I’ve been on medical leave since June 27th as a result of a serious bicycling accident, which occurred when riding with my regular early morning cycling group. I very much appreciate the well-wishes sent to me and my family over the past few weeks, and wanted to update you all on my condition. As a result of the accident, I sustaine

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 24, 2019 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction (Commission File Number) (IRS

IDEXX Laboratories Elects Sam Samad to Board of Directors

EXHIBIT 99.1 FOR IMMEDIATE RELEASE IDEXX Laboratories Elects Sam Samad to Board of Directors WESTBROOK, Maine, July 18, 2019 - IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, announced today the election of Sam Samad, the Senior Vice President and Chief Financial Officer of Illumina, Inc., as a member

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 16, 2019 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction (Commission File Number) (IRS

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 28, 2019 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction (Commission File Number) (IRS

IDEXX Laboratories Chairman, President and Chief Executive Officer, Jonathan Ayers, Taking Medical Leave of Absence

Exhibit 99.1 IDEXX Laboratories Chairman, President and Chief Executive Officer, Jonathan Ayers, Taking Medical Leave of Absence Jay Mazelsky, Executive Vice President, Companion Animal Group, Appointed Interim President and Chief Executive Officer WESTBROOK, Maine, July 1, 2019 /PRNewswire/ - IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice s

Conflict Minerals Report for the calendar year ended December 31, 2018

Exhibit 1.01 Conflict Minerals Report Overview IDEXX Laboratories, Inc. has included this Conflict Minerals Report as an exhibit to its Form SD for the calendar year ended December 31, 2018 as provided for in Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Form SD (collectively, the “Conflict Minerals Rule”). The date of filing of this Conflict Minerals R

IDXX / IDEXX Laboratories, Inc. SD - - SD

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) One IDEXX Drive, Westbrook, Maine 04092 (Address of principal executive of

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2019 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction (Commission File Number) (IRS Em

IDEXX Laboratories Announces First Quarter Results

Exhibit 99.1 IDEXX Laboratories Announces First Quarter Results WESTBROOK, Maine, May 1, 2019 /PRNewswire/ - Reports revenue growth of 7% on a reported basis and 10% on an organic basis, driven by CAG Diagnostics recurring revenue growth of 9% reported and 12% organic Delivers EPS of $1.17, representing 16% growth on a reported basis and 27% on a comparable constant currency basis Maintains 2019 r

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 1, 2019 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction (Commission File Number) (IRS Em

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 000-19271 IDE

IDXX / IDEXX Laboratories, Inc. DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) þ Filed by the Registrant c Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: c Preliminary Proxy Statement c Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) c Defin

IDXX / IDEXX Laboratories, Inc. DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) þ Filed by the Registrant ¨ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Defin

Multicurrency Note Purchase and Private Shelf Agreement, dated as of December 19, 2014, among the Company, as issuer, and Metropolitan Life Insurance Company, MetLife Insurance Company USA, Symetra Life Insurance Company, MetLife Insurance K.K., AXIS Reinsurance Company, and Union Fidelity Life Insurance Company, as purchasers

Exhibit 10.1 Execution Version IDEXX LABORATORIES, INC. $75,000,000 3.25% Series A Senior Notes due February 12, 2022 $75,000,000 3.72% Series B Senior Notes due February 12, 2027 $50,000,000 (or Foreign Currency Equivalent) Private Shelf Facility MULTICURRENCY NOTE PURCHASE AND PRIVATE SHELF AGREEMENT Dated December 19, 2014 TABLE OF CONTENTS Page 1. AUTHORIZATION OF NOTES 1 Section 1.1. Authoriz

First Amendment to Multicurrency Note Purchase and Private Shelf Agreement, dated March 14, 2019, among the Company, as issuer, and IDEXX Distribution, Inc., IDEXX Operations, Inc., and OPTI Medical Systems, Inc., each as a subsidiary guarantor, and Metropolitan Life Insurance Company, MetLife Reinsurance Company of Bermuda, Ltd., Brighthouse Life Insurance Company, Symetra Life Insurance Company, and AXIS Reinsurance Company

Exhibit 10.2 Conformed Copy FIRST AMENDMENT TO MULTICURRENCY NOTE PURCHASE AND PRIVATE SHELF AGREEMENT This FIRST AMENDMENT TO MULTICURRENCY NOTE PURCHASE AND PRIVATE SHELF AGREEMENT, dated as of March 14, 2019 (the “First Amendment”) is made by and among IDEXX Laboratories, Inc., a Delaware corporation (the “Company”), each of the Subsidiary Guarantors set forth on the signature pages to this Fir

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 14, 2019 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction (Commission File Number) (IRS

Form of High-Performer Restricted Stock Unit Agreement pursuant to the 2018 Stock Incentive Plan (filed herewith).

EXHIBIT 10.28 High Performer Restricted Stock Unit Agreement Granted Under IDEXX Laboratories, Inc. 2018 Stock Incentive Plan 1. Grant of Restricted Stock. IDEXX Laboratories, Inc., a Delaware corporation (the “Company”), hereby grants to the Participant a Restricted Stock Unit Award consisting of the number of Restricted Stock Units (“RSUs”) stated in this Agreement. Each RSU represents the right

Form of Director Stock Option Agreement (filed as Exhibit 10.24 to Annual Report on Form 10-K for the year ended December 31, 2018, File No. 0-19271, and incorporated by reference herein).

Exhibit 10.24 Director Stock Option Agreement Granted Under IDEXX Laboratories, Inc. 2018 Stock Incentive Plan 1. Grant of Option. IDEXX Laboratories, Inc., a Delaware corporation (the “Company”), hereby grants to the member of the Company’s Board of Directors named on the opposite side of this Agreement (the “Optionee”), an option, pursuant to the Company’s 2018 Stock Incentive Plan (the “Plan”),

Form of Employee Restricted Stock Unit Agreement for grants in 2018 and 2019

EXHIBIT 10.26 Employee Restricted Stock Unit Agreement Granted Under IDEXX Laboratories, Inc. 2018 Stock Incentive Plan 1. Grant of Restricted Stock Units. (a) Grant. IDEXX Laboratories, Inc., a Delaware corporation (the “Company”), hereby grants to the Participant a Restricted Stock Unit Award consisting of the number of Restricted Stock Units (“RSUs”) stated in this Restricted Stock Unit Agreeme

IDXX / IDEXX Laboratories, Inc. 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) T ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 0-19271 IDEXX LABORATO

Form of Employee Performance-Based Restricted Stock Unit Agreement

EXHIBIT 10.27 Performance-Based Restricted Stock Unit Agreement Granted Under IDEXX Laboratories, Inc. 2018 Stock Incentive Plan 1. Grant of Performance-Based Restricted Stock Units. (a) Grant. IDEXX Laboratories, Inc., a Delaware corporation (the “Company”), hereby grants to the Participant a Restricted Stock Unit Award consisting of the number of Restricted Stock Units (“RSUs”) stated in this Pe

Subsidiaries of the Company (filed herewith)

Exhibit 21 IDEXX LABORATORIES, INC. SUBSIDIARIES OF THE COMPANY Legal Entity Name Jurisdiction of Incorporation or Formation 342 Saco Street, LLC Maine Beijing IDEXX-Yuanheng Laboratories Co. Limited China IDEXX Animana B.V. Netherlands IDEXX Brasil Laboratórios Ltda. Brazil IDEXX Brasil Participações Ltda. Brazil IDEXX Diagnostic Limited Ireland IDEXX Diavet AG Schwyz IDEXX Distribution, Inc. Mas

Form of Employee Stock Option Agreement for grants in 2018 and 2019

EXHIBIT 10.25 Employee Stock Option Agreement Granted Under IDEXX Laboratories, Inc. 2018 Stock Incentive Plan 1. Grant of Option. (a)Grant. IDEXX Laboratories, Inc., a Delaware corporation (the “Company”), pursuant to the Company’s 2018 Stock Incentive Plan (the “Plan”) and this Employee Stock Option Agreement, including any exhibit, appendix or addendum hereto (the “Agreement”), hereby grants to

IDXX / IDEXX Laboratories, Inc. / BAMCO INC /NY/ - NONE Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10)* Idexx Laboratories Inc. (Name of Issuer) Common (Title of Class of Securities) 45168D104 (CUSIP Number) Calendar Year 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w

IDXX / IDEXX Laboratories, Inc. / VANGUARD GROUP INC Passive Investment

idexxlaboratoriesinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6 )* Name of issuer: IDEXX Laboratories Inc Title of Class of Securities: Common Stock CUSIP Number: 45168D104 Date of Event Which Requires Filing of this Statement: December 31, 2018 Check the appropri

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 1, 2019 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction (Commission File Number) (I

IDEXX Laboratories Announces Fourth Quarter and Full Year 2018 Results

Exhibit 99.1 IDEXX Laboratories Announces Fourth Quarter and Full Year 2018 Results WESTBROOK, Maine, Feb. 1, 2019 /PRNewswire/ - Achieves revenue growth in Q4 of 9% on a reported basis and 10% on an organic basis, driven by CAG Diagnostics recurring revenue growth of 12% reported and 13% organic Reports 15% year-over-year increase in Catalyst placements at new or competitive accounts in Q4, suppo

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 1, 2018 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction (Commission File Number) (I

IDEXX Laboratories Announces Third Quarter Results

IDEXX Laboratories Announces Third Quarter Results WESTBROOK, Maine, Nov. 1, 2018 /PRNewswire/ - Reports revenue growth of 11% on a reported basis and 12% on an organic basis, driven by CAG Diagnostics recurring revenue growth of 12% reported and 13% organic Delivers EPS of $1.05, a 33% increase year-over-year on a reported basis or 39% on a comparable constant currency basis Refines 2018 reported

IDXX / IDEXX Laboratories, Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 000-19271

IDEXX Laboratories Announces Second Quarter Results

EX-99.1 2 tv499777ex99-1.htm EXHIBIT 99.1 IDEXX Laboratories Announces Second Quarter Results WESTBROOK, Maine, Aug. 1, 2018 /PRNewswire/ - Reports revenue growth of 14% on a reported basis and 12% on an organic basis, driven by CAG Diagnostics recurring revenue growth of 15% reported and 13% organic Achieves 3,241 premium instrument placements, representing 21% year-over-year growth Delivers EPS

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 1, 2018 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 000-19271 01-0393723 (State or other jurisdiction (Commission File Number) (IRS

IDXX / IDEXX Laboratories, Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . COMMISSION FILE NUMBER: 000-19271 IDEX

Retirement Agreement dated May 24, 2018 between the Company and Jacqueline L. Studer (filed as Exhibit 10.1 to Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2018, File No. 0-19271.

EX-10.1 2 idxx2018q210-qexhibit101.htm EXHIBIT 10.1 EXHIBIT 10.1 May 24, 2018 Jacqueline L. Studer Re: Retirement Agreement Dear Jackie: This letter confirms the terms for your retirement from service as Corporate Vice President, General Counsel and Corporate Secretary at IDEXX Laboratories, Inc. Your retirement from IDEXX Laboratories, Inc. and/or its subsidiaries or affiliates (hereinafter colle

IDXX / IDEXX Laboratories, Inc. S-8 POS

As filed with the Securities and Exchange Commission on July 19, 2018 Registration No.